With average yearly treatment costs exceeding $100,000, cancer drugs in the US cost nearly twice as much as anywhere else in the world. Drug pricing is driven by state and federal policies, as well as clinical advances that allow the development of specific treatments for targeted populations. It can be difficult to find any correlation between a drug’s price and the social value or efficacy of the drug. We recently published a case study comparing three cancer treatments, one for colorectal cancer and two for multiple myeloma, illustrating how the net health benefits versus costs for new treatments can vary widely.
Read Full Article »
